Navigating the PCSK9 Inhibitor Frontier

PROGRAM DESCRIPTION This crossfire is designed to educate clinicians regarding the latest clinical trial evidence for PCSK9 inhibitors (PCSK9i), emphasizing results from studies that evaluated coronary risk and cardiovascular outcomes. ...

PROGRAM DESCRIPTION
This crossfire is designed to educate clinicians regarding the latest clinical trial evidence for PCSK9 inhibitors (PCSK9i), emphasizing results from studies that evaluated coronary risk and cardiovascular outcomes. They will discuss the efficacy and safety data supporting these therapies, and the role of new therapies alongside traditional dyslipidemia treatment options. The activity will go beyond a simple overview of the trial results to guide clinicians in how to interpret the clinical implications of the findings to improve the management of CV risk in their patients.

EDUCATIONAL OBJECTIVES
At the conclusion of this activity, participants should be better able to:Determine optimal LDL-C target goals in high-risk individuals in light of current consensus recommendationsReview the latest clinical trial data for the novel LDL-C lowering agents, PCSK9 inhibitors, and their potential application to address ASCVD risk in clinical practiceDiscuss new data and how it will benefit individualized treatment plans to improve outcomes and lower the risk of cardiovascular events for patients with dyslipidemia

---

Write the first review

Resource tags